Dawa Limited

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 9.95 Industry: Pharmaceutical and Medicine Manufacturing Available in: English Format: PDF Download Buy full report

What’s included?

This report extracts all available information about this company from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Baba Dogo Road
Nairobi; Nairobi; Map
Postal Code: P.O. Box 16633-00620

Tel: +254-20 356
Fax: +254-20-856



Company Description
Dawa Limited is a Pharmaceutical (Manufacturing) company based in Kenya, manufacturing Pharmaceuticals of the highest quality. Dawa Limited, formerly known as Dawa Pharmaceuticals, which was acquired by Medisel (K) Ltd in August 2004, started its operations in 1977. Since the acquisition it has undergone a major face-lift in manufacturing facilities with the focus being on the quality control department.
NAICS Industry Classification
Key Executives

You’re in good company

EMIS company reports are used extensively by the world’s biggest companies, financial institutions, professional service companies and universities to assess businesses in emerging markets.


company profiles

We have information on both public and private companies across 125 countries.



EMIS is the go-to information source on emerging market companies for the world’s most prestigious businesses.

Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

Contact us to learn more about our business solutions.
Sign up to our newsletter

Make sure you’re not the last to know by getting the latest insights on emerging markets straight to your inbox.